Tricyclic antidepressants

35,210views

Tricyclic antidepressants

NP Pharm

NP Pharm

Introduction to pharmacology
Pharmacokinetics: Drug absorption and distribution
Pharmacokinetics: Drug metabolism
Pharmacokinetics: Drug elimination and clearance
Pharmacodynamics: Drug-receptor interactions
Pharmacodynamics: Agonist, partial agonist and antagonist
Pharmacodynamics: Desensitization and tolerance
Drug administration and dosing regimens
Non-steroidal anti-inflammatory drugs
Acetaminophen (Paracetamol)
Opioid agonists, mixed agonist-antagonists and partial agonists
Opioid antagonists
Glucocorticoids
Osteoporosis medications
Antigout medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Medications for neurodegenerative diseases
Anti-parkinson medications
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Adrenergic antagonists: Beta blockers
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Positive inotropic medications
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Antihistamines for allergies
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Pulmonary corticosteroids and mast cell inhibitors
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Miscellaneous hypoglycemics
Hypoglycemics: Insulin secretagogues
Non-corticosteroid immunosuppressants and immunotherapies
Methemoglobinemia
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Anti-tumor antibiotics
Antimetabolites for cancer treatment
Monoclonal antibodies
DNA alkylating medications
PDE5 inhibitors
Androgens and antiandrogens
Adrenergic antagonists: Alpha blockers
Estrogens and antiestrogens
Progestins and antiprogestins
Aromatase inhibitors
Uterine stimulants and relaxants
Acid reducing medications
Laxatives and cathartics
Antidiarrheals
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Atypical antidepressants
Tricyclic antidepressants
Monoamine oxidase inhibitors
Typical antipsychotics
Atypical antipsychotics
Nonbenzodiazepine anticonvulsants
Lithium
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
DNA synthesis inhibitors: Metronidazole
Protein synthesis inhibitors: Tetracyclines
Protein synthesis inhibitors: Aminoglycosides
Miscellaneous protein synthesis inhibitors
Antituberculosis medications
Antimetabolites: Sulfonamides and trimethoprim
Mechanisms of antibiotic resistance
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Hepatitis medications
Herpesvirus medications
Azoles
Miscellaneous antifungal medications
Anthelmintic medications
Anti-mite and louse medications
Antimalarials

Transcript

Watch video only

Tricyclic antidepressants, or TCAs, are mainly used to treat major depressive disorder.

This disorder causes a persistent feeling of sadness and loss of interest in everyday activities.

Even though the exact cause of depression is still unknown, there's some evidence that suggests it’s related to low levels of neurotransmitters like serotonin, norepinephrine, and dopamine.

Tricyclic antidepressants work by increasing the levels of serotonin and norepinephrine to alleviate the symptoms of depression.

Alright, now within the brain, there are many different types of neurons, but we’re just going to focus on two: serotonergic neurons which produce serotonin, and noradrenergic neurons which produces norepinephrine.

Each of these neurons synthesizes and stores their neurotransmitters in small vesicles.

So, when an action potential reaches the presynaptic membrane, these vesicles fuse with the membrane, releasing neurotransmitters into the synaptic cleft.

Once released, serotonin or 5-HT binds to 5-HT2 receptors on the postsynaptic membrane, thereby increasing neural stimulation and regulating mood, feeding, and reproductive behavior.

On the other hand, norepinephrine binds to norepinephrine receptors on the postsynaptic membrane, boosting alertness.

As long as there’s a high enough concentration of neurotransmitters in the synaptic cleft, the postsynaptic neurons will continue to fire.

Now, serotonergic neurons, on their presynaptic membrane, have serotonin transporters or SERT, while noradrenergic neurons have norepinephrine transporters or NET.

These membrane proteins transport the serotonin and norepinephrine in the synaptic cleft back into presynaptic neurons.

This leads to decreased neurotransmitter concentration within the synaptic cleft, causing the postsynaptic neurons to stop firing.

So, in conditions such as major depressive disorder, tricyclic antidepressants can be used to increase the levels of serotonin and norepinephrine.

Tricyclic antidepressants are subdivided into 2 main groups: tertiary TCAs, which include amitriptyline, imipramine, and clomipramine; and secondary TCAs, which include desipramine and nortriptyline.

Tertiary TCAs are also known as non-selective tricyclic antidepressants and they inhibit both serotonin transporters and norepinephrine transporters, while secondary TCAs, which are also known as selective tricyclic antidepressants, inhibit only norepinephrine transporters.

This way, tricyclic antidepressants are increasing levels of serotonin and norepinephrine or just norepinephrine within the synaptic cleft, thus increasing the activity of postsynaptic neurons.

It's important to note that these medications are slow-acting because it takes time for serotonin and norepinephrine to accumulate within the synaptic cleft. Because of this, it usually takes 2-4 weeks before improvements can be seen.

Even though they’re very effective in the treatment of depression, tricyclic antidepressants are not considered as the first line therapy due to their severe side effects.

They’re typically reserved for when there is no response to other antidepressants, such as selective serotonin reuptake inhibitors, or SSRIs.

Other indications for TCAs include phobic disorders, chronic neuropathic pain, like peripheral neuropathy, and as migraine prophylaxis.

Now, for medication specific indications, clomipramine can be used in the treatment of obsessive-compulsive disorder, or OCD, while imipramine is used in the treatment of nocturnal enuresis, which is involuntary urination while asleep.

Besides serotonin and norepinephrine transporters, TCAs also block histamine H1 receptors, causing sedation; alpha 1 receptors, causing orthostatic hypotension; and muscarinic receptors, causing atropine-like side effects.

Atropine-like side effects occur more commonly with tertiary TCAs and they include dry mouth, tachycardia, urinary retention, confusion, and hallucinations.

TCAs can also cause serotonin syndrome, which is a life-threatening condition caused by serotonin accumulation and over stimulation of the nervous system.

Key Takeaways

Tricyclic antidepressants (TCAs) are a class of medications used to treat depression, anxiety disorders, migraine, and chronic pain. They are named for their chemical structure, which includes three rings of atoms.

TCAs work by preventing serotonin and norepinephrine reuptake from the synaptic cleft, thus enhancing the effect of both neurotransmitters on postsynaptic neurons. Some common TCAs include amitriptyline, imipramine, and nortriptyline.

Common side effects include dry mouth, blurred vision, constipation, dizziness, and drowsiness. TCAs can also cause more serious side effects, such as heart rhythm disturbances, seizures, and an increased risk of suicide, particularly in younger individuals.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Mechanism of action of antidepressant medications" J Clin Psychiatry (1990)
  5. "Tricyclic antidepressant pharmacology and therapeutic drug interactions updated" British Journal of Pharmacology (2007)
  6. "Tricyclic antidepressant overdose: a review" Emerg Med J (2001)
  7. "Neuroleptic malignant syndrome and serotonin syndrome" Thermoregulation: From Basic Neuroscience to Clinical Neurology, Part II (2018)